MedTrace Logo

Light Therapy for Elderly Depression

NCT00332670 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2008-08-15

No results posted yet for this study

Summary

The purpose of this study is to investigate the following two hypotheses:

1. Treatment with bright light improves their sleep, mood, concentration and self-sufficiency of elderly depressed subjects. This clinical improvement is accompanied by decreases in cortisol/DHEA ratio and increases in melatonin concentration in urine and saliva.
2. The eventual beneficial effect of bright light treatment can be predicted by the presence of sleep-wake rhythm disturbances as found using muscle activity registration, and by cortisol/DHEA and melatonin concentrations in saliva and urine over the day and the night.

Conditions

Interventions

PROCEDURE

10.000lux blue 1 hour every day during three weeks

10.000lux during 60 minutes, starting 1 hour after wake-up, during 3 weeks

PROCEDURE

50lux dim red 1 hour every day during three weeks

50 lux red light, 60 minutes every morning, starting 1 hour after wake-up, during three weeks

Sponsors & Collaborators

  • Netherlands Institute for Brain Research, Amsterdam, The Netherlands.

    collaborator UNKNOWN

  • GGZ Buitenamstel

    lead OTHER

Principal Investigators

  • Witte JG Hoogendijk, prof. dr. · Center for Neurogenomics and Cognitive Research, Free University, Amsterdam, the Netherlands; Department of Psychiatry VU University Medical Center, Amsterdam, The Netherlands; GGZ Buitenamstel, Amsterdam, The Netherlands

  • Eus van Someren, PhD · Netherlands Institute for Brain Research, Amsterdam, The Netherlands; VU University Medical Center, Amsterdam, The Netherlands

  • Marjan MA Nielen, PhD · Center for Neurogenomics and Cognitive Research, Free University, Amsterdam, the Netherlands; Department of Psychiatry VU University Medical Center, Amsterdam, The Netherlands; GGZ Buitenamstel, Amsterdam, The Netherlands

  • Ritsaert Lieverse, MD · Center for Neurogenomics and Cognitive Research, Free University, Amsterdam, the Netherlands; Department of Psychiatry VU University Medical Center, Amsterdam, The Netherlands; GGZ Buitenamstel, Amsterdam, The Netherlands

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332670 on ClinicalTrials.gov